Matrix metalloproteinases and disease severity among PI*MZ and PI*ZZ individuals in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort
Our study shows that alveolar MMP3 and MMP15 may uniquely contribute to disease among PI*MZ individuals, raising the possibility that they could serve as biomarkers or therapeutic targets in this highly prevalent COPD phenotype. Furthermore, we show that MMP10 may serve a protective effect. In aggregate, these data support further studies of the MMP pathway among lung-affected PI*MZ individuals, as they may serve as biomarkers or pharmacological targets in future studies.
Authors
- Charlie Strange (ORCID: https://orcid.org/0000-0002-8109-8067)
- Russell Paul Bowler (ORCID: https://orcid.org/0000-0003-4651-363X)
- Katherine Pratte (ORCID: https://orcid.org/0000-0003-3358-8907)
- James K. Stoller (ORCID: https://orcid.org/0000-0002-9636-5770)
- Vickram Tejwani (ORCID: https://orcid.org/0000-0003-2100-6148)
- Karina A. Serban (ORCID: https://orcid.org/0000-0002-9372-3034)
- Naftali Kaminski (ORCID: https://orcid.org/0000-0001-5917-4601)
- Victor E. Ortega (ORCID: https://orcid.org/0000-0001-6361-7372)
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Medical University of South Carolina (US)
- WinnMed (US)
- National Jewish Health (US)
- Yale University (US)
- University of Florida (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/bmjresp-2025-003585
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute